Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
N/A N=102 Iron Parameters in Non-anemic First Trimester Gravidas
Iron Deficiency (Without Anemia) · Pregnancy
Primary: Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity — 9; 3; 6; 38 Participants
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 4 N=13 Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Iron Deficiency Anemia · Heavy Menstrual Bleeding · Abnormal Uterine Bleeding
Primary: Percentage of Eligible Patients Enrolled. — 13 Participants
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
Phase 2 N=74 Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Pregnancy
Primary: Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD). — 35; 11 Participants
N/A N=127 Iron Treatment for Young Children With Non-anemic Iron Deficiency
Non-anemic Iron Deficiency
Primary: Early Learning Composite (ELC) From the Mullen Scales of Early Learning — 113.0; 113.5; 110.48; 107.94 units on a scale
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69
Phase 3 N=1 Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
Iron Deficiency Anemia · Iron-deficiency
Primary: Percentage of Eligible Patients Enrolled — 1; 0 Participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 3 N=2,018 Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Anemia
Primary: Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC. — 6; 22 participants
Phase 3 N=703 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Anemia
Primary: Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC — 17; 11 participants
Phase 3 N=634 A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol — 2.6 g/dL — p=<0.0001
Phase 3 N=735 Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
Anemia
Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAE's) — 5; 9 participants
N/A N=197 Iron Depletion and Replacement in Blood Donors
Anemia
Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants
Phase 2 N=149 Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
N/A N=150 IV Iron for the Anemia of Traumatic Critical Illness
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
Phase 4 N=40 Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
Anemia, Iron Deficiency · Delivery Complication
Primary: Hemoglobin Level — 12; 12 grams/deciliters
N/A N=251 Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years
Iron Deficiency
Primary: The Primary Outcome is Iron Depletion, and Will be Defined as Serum Ferritin <10 mcg/L. — 64; 71; 13; 10 participants — p=0.42
Phase 3 N=594 Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
Anemia
Primary: Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period — 174; 114 participants
Phase 3 N=80 Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
Pregnancy Related · Anemia, Iron Deficiency
Primary: Median Change in Hemoglobin Value Before and After Intervention — 10.95; 11.45 g/dL — p=< 0.001
Phase 3 N=160 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
Anemia
Primary: The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's) — 60; 59 participants
Phase 3 N=812 A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Participants Who Achieved A ≥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5 — 252; 5; 386; 7 Participants — p=<0.0001
Phase 3 N=7 Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044
Iron Deficiency Anemia
Primary: Change in Hemoglobin From Baseline to Day 35 — 0.70 g/dL — p=0.1711
Phase 2 N=49 Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Iron Deficiency Anemia
Primary: Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane) — -11.90; -1.06; -12.37; -11.14 mg